The panel agrees prostate cancer diagnostic pathway improvements have reduced some of the harms associated with PSA testing but several areas of uncertainty remain, such as appropriate PSA referral values, retesting intervals in men who are at higher risk, and the extent to which overdiagnosis or overtreatment have reduced. This evidence concerns the gene KLK3 and prostate carcinoma.